The t(7;12)(q36;p13) is a recurrent abnormality in acute myeloid leukemia (AML) of childhood. The involved gene on chromosome 12 is TEL; the 7q36 partner gene has not been identified. We describe morphologic, molecular and cytogenetic characterization of two cases of 7q36/12p13-associated AML that provide important insights regarding the consequences of this rearrangement. First, the molecular organization of the breakpoint regions differ significantly: one case is a reciprocal 7;12 translocation (RTR); the other has an insertion of 7q into 12p (INS). While 12p13 breakpoints in both patients interrupt TEL intron 1, the centromere to telomere orientation of the 7q36 sequences relative to the TEL sequences are inverted in INS compared to RTR. This difference makes it difficult to postulate a mechanism whereby both patients could produce a common fusion transcript. Further, no evidence was obtained for any TEL-containing fusion transcripts. Finally, we report the first cloning of a 7;12 genomic breakpoint (from RTR) and find that it maps to a site 30 kbp proximal to the HLXB9 gene in 7q36. Together, these data suggest that, unlike most leukemia-associated chromosomal rearrangements, the important consequence of the t(7;12) is likely not the generation of a novel fusion transcript, but instead the inactivation of TEL and/or a gene at 7q36.
Introduction
Several collaborative groups recently have identified the t(7;12)(q36;p13), often accompanied by trisomy for chromosome 19 or in some cases by trisomy 8, as a recurring abnormality in acute leukemia of early childhood, most frequently associated with myeloid malignancies. [1] [2] [3] Data from the Dutch Childhood Leukemia Study Group suggest that this t(7;12) may account for almost 20% of AML in children less than 18 months of age (excluding children with Down syndrome). 1 The majority of these patients have had a poor clinical outcome; thus, the t(7;12) may be an important prognostic indicator.
Detection of the t(7;12) in most published cases was dependent upon or facilitated by the utilization of FISH, as the small sizes of the regions of 7q and 12p that are involved make the translocation difficult to detect by conventional G-banding. Analysis of cases in which there is loss of the der(7) or cases in which there are three-way translocations with material from 7q36 translocated to 12p13, but without formation of the reciprocal der (7) , indicate that the critical fusion takes place on the der (12) . Most [1] [2] [3] [4] but not all 2 of the studied breakpoints within 12p13 fall within the TEL (ETV6) gene. [1] [2] [3] [4] The breakpoint on chromosome 7 has not been localized to any known gene. One report has described the detection of fusion transcripts that include sequences from the HLXB9 gene at 7q36 fused in frame to those of TEL. However, FISH data indicated that the chromosomal breakpoints for these patients were not within HLXB9 (Ref. 5 and see below).
TEL (translocation-Ets-leukemia or ETV6), a member of the Ets family of transcription factors, is a transcriptional repressor 6, 7 that is proposed to function as a tumor suppressor, a property that may be mediated in part by its transcriptional repression of stomelysin-1. 8 TEL is ubiquitously expressed in the adult and is essential in early development. 9, 10 TEL was originally identified as the fusion partner of the PDGF␤R gene in t(5;12)(q33;p13) associated with chronic myelomonocytic leukemic (CMML). 11 Since that time, up to 41 different chromosome bands have been identified as TEL fusion partners, some of which comprise complex rearrangements. 12, 13 As with other chromosomal translocations associated with leukemias, most of those involving TEL result in the generation of novel fusion proteins that are of demonstrated or presumed importance in the associated diseases. 11, [14] [15] [16] [17] [18] [19] [20] [21] There also have been several reported cases in which translocations involving TEL do not give rise to a detectable in-frame fusion product. 22, 23 It has been suggested that in these cases, inactivation of TEL, either alone or in combination with the affected partner gene, might be important in disease. Alternatively, it has also been proposed that TEL translocations that do not generate a functional fusion transcript and that involve the 5Ј end of TEL might instead result in up-regulation of flanking genes. 24 . In this report, we describe the molecular and cytogenetic characterization of two young patients with AML associated with 7q36/12p13 abnormalities. Despite the fact that their diseases share very similar clinical and morphologic findings, the cytogenetic and molecular genetic organization of the underlying 7q36/12p13 abnormalities are different. These differences, in combination with data we derive from cloning the 7q36/12p13 breakpoint in the RTR case and from the absence of detectable TEL fusion transcripts, lead to the proposal that the critical ramification of the t(7;12) or its variants is the concomitant inactivation of gene(s) at 7q36 and TEL rather than the generation of a novel fusion transcript.
Materials and methods

Patients
Patient RTR, a male child, was diagnosed with acute myeloid leukemia, with CNS involvement, at 15 months of age. He was entered on Children's Cancer Group protocol 2961, but relapsed 8 months into therapy with bone marrow disease and bilateral chloromas on his hips. Subsequent therapy included radiation to the hips, chemotherapy per CCG protocol 2951 and an unrelated allogeneic bone marrow transplant. Recur-rent disease was evident within 100 days post-transplant, and death ensued.
Patient INS, a male child, was diagnosed with AML at 7 months of age. At presentation, he had hyperuriciemia, renal failure and CNS involvement. He was entered on CCG protocol 2961 and by day 28 had achieved clinical, morphologic and cytogenetic remission. After relapsing twice over the course of the next few months, he received a related, allogeneic bone marrow transplant. He is now 2 years posttransplant and continues to be in remission with 100% donor engraftment.
Cytogenetic analyses
Chromosomal analyses were performed on G-banded metaphase cells obtained after short-term unstimulated culture of the diagnostic bone marrow aspirates per routine cytogenetic methods. The resulting karyotypes were designated according to the ISCN, 1995. 25 
Fluorescence in situ hybridization
Commercial probes used for FISH included alpha satellite probes for the centromeric regions of chromosomes 7 and 12 (Vysis, Downer's Grove, IL, USA). To identify the breakpoints within TEL, overlapping cosmids spanning TEL intron 1 (179A6, 15A4, 67C6, 50F4 see Figure 1 ; obtained from Dr Peter Marynen (Center for Human Genetics, University of Leuven, Leuven, Belgium) and 10A, a 10 kbp probe PCRamplified from the 5Ј-end of cosmid 50F4 using the primers (5Ј-GTTCTCTCTCTCCTGAAGTTG) and (5Ј-CTGTAAAGCCC AACCTACCG) were used. PCR products were purified using Spin-X gel-purification columns (Costar; Corning, Corning, NY, USA). FISH probes used to map the breakpoint on chromosome 7q included: FRS236, an approximately 40 kb 
Method
FISH was performed on metaphase cells prepared from residual cell pellets that had been preserved in methanol:acetic acid fixative after harvesting for the diagnostic cytogenetic studies. Commercially obtained probes were purchased pre-labeled with spectrum orange or spectrum green and applied according to the manufacturer's instructions. Cosmids were labeled by nick translation (GIBCO BRL Nick translation kit; Gibco BRL, Grand Island, NY, USA) with digoxigenin-11-dUTP (Boehringer, Mannheim, Germany), followed by precipitation and then resuspension in 1:1 formamide:20% dextran sulfate. FISH was performed according to standard procedures, including denaturation of probes and slides at 70ºC, overnight hybridization with probe, sequential washes in 2 × SSC and sodium phosphate buffer with 0.1% NP-40. Most hybridizations involved dual-color detection wherein a chromosome 7-or chromosome 12-centromere specific probe was hybridized along with the cosmid probe for 7q36 or 12p13. Spectrum orange and spectrum green-labeled centromere probes could be visualized directly; digoxigeninlabeled probes were first detected with fluorescein anti-dig (Ventana Medical Systems, Tucson, AZ, USA). All preparations were counterstained with DAPI (Vysis) and visualized on an Olympus BX60 microscope outfitted with DAPI, FITC, rhodamine, dual pass and triple pass filters (Chroma, Brattle-boro, VT, USA), and imaged with CytoVysion software (Applied Imaging, Santa Clara, CA, USA). When needed for specific localization of the hybridization signals, sequential Gbanding to FISH was performed as previously described. 26 
Cell lines
KG-1, a human myeloid cell line derived from a patient with acute myeloid leukemia, was obtained from ATCC (No CCL-246) and maintained in Iscove's modified Dulbecco's medium supplemented with 20% defined bovine serum. 293 cells, a human embryonic kidney epithelial cell line, were obtained from Dr Nikunj Somia (Institute of Human Genetics, University of Minnesota, MN, USA) and maintained in DMEM supplemented with 10% defined bovine serum.
Genomic DNA preparation and inverse PCR (iPCR)
Genomic DNA was isolated from the KG-1 and 293 cell lines using SDS lysis followed by protease digestion and phenol:-chloroform extraction. Genomic DNA was prepared from the same fixed, residual cell pellets described above for FISH. For this purpose, the PureGene Cell and Tissue Kit (Gentra Systems, MN, USA) was used according to the manufacturer's instructions. For inverse PCR (iPCR), 500 ng aliquots of genomic DNA were digested individually with different restriction enzymes according to the manufacturer's instructions. After purification, the DNA was resuspended in water for ligation with 5 U of T4 DNA ligase (Invitrogen-Life Technologies, Carlsbad, CA, USA) in a total reaction volume of 200 l (2.5 ng DNA/l) at 16ºC overnight. Ligation reactions were extracted with phenol:chloroform, precipitated, and resuspended in 25 l water for PCR reactions.
For each iPCR, 2 l of ligated genomic DNA was amplified using 15 pmol primers and the Advantage 2 polymerase system (Clontech, Palo Alto, CA, USA) in a total reaction volume of 50 l. Second-round iPCR reactions were then carried out using 5 l of a 10 −2 dilution of the first-round iPCR and 15 pmol of nested primers. As described in Results, all reactions except one gave rise to wild-type products. The exception was primer set 10 that revealed the presence of a novel tumorspecific fragment. Sequences of the first round primer set 10 were: B10 (5Ј-TTCGGTAGGTTGCTGTTTACTCTG), C10 (5Ј-ATGCAAATCAAAGCCACGACGAG) while those of the second round primer set were: E10 (5Ј-CTTTTGCCGTGCAGA AGC-TCTTT), D10 (5Ј-GTCTCACACCAGTCAG-AATGCTAT). Products of interest were gel-purified (Gel Extraction Kit, Qiagen, Valencia, CA, USA) and cloned using the TOPO TA Cloning Kit (Invitrogen-Life Technologies).
Amplification reactions to verify the breakpoint identified in iPCR were carried out in 50 l reactions using 100 ng RTR genomic DNA, the Advantage 2 polymerase system, and 15 pmol of the following primers: for the der(7) fusion amplification, primers der(7)-F1 (5Ј-AGGACGAGAAGCTGTGGGTT ATTG) and der(7)-R1 (5Ј-AGATTCATTCTCTCCACCCCCA) were used in PCR 1 followed by der(7)-F2 (5Ј-GATAGGAAAA GGGGCTTCTGAGGA) and der(7)-R2 (5Ј-GTGACCGCCTTA GCTCCCTGTC) in PCR 2. For the der(12) fusion amplification, primers der(12)-F1 (5Ј-GGCAAAGGCATGGAGAAAAGGGA) and der(12)-R1 (5Ј-GATACTGTGAATAGCGTGGCAG) were used in PCR 1 followed by der(12)-F2 (5Ј-GGAAAGCAGTAG GGAAGCTCCTC) and der(12)-R2 (5Ј-GACAGTATCTCGTCG TGGCTTTGA) in PCR 2. Second-round amplification was performed using 2 l PCR 1 as template.
RNA preparation and RT-PCR
Total RNA from cell lines and from the INS and RTR patients was prepared by the guanidinium isothiocyanate method. 35 Approximately 50 ng of KG-1 and patient total RNA were reverse transcribed individually using 10 pM of TEL-R2 (5Ј-CTTCTTCGTAGTTCTGATGTATG) or HLXB9-1092R (5Ј-TGCTGTAGGGGAAATGGTCCTCG) and the ThermoScript RT-PCR system (Invitrogen-Life Technologies). First-round PCRs were performed using 2 l cDNA, 15 pmol primers, 500 M dNTPs and the Advantage 2 polymerase system. Second round PCRs were performed using 2 l of the first-round PCR samples and the FailSafe PCR Kit Mix H (Epicentre, Madison, WI, USA) and were then analyzed by 2% agarose gel electrophoresis. RT-PCRs were performed using the following primer combinations. For wild-type TEL, PCR 1: TEL-F10 (5Ј-GGAAA AACCTGAGAACTT) and TEL-R1 (5Ј-CTGAAGGAGTTCATAG AGCACATCAC), PCR 2: TEL-F7 (5Ј-CTGATCCTCTCTCGCTG TGA) and TEL-R10 (5Ј-ATCGATAGCGAAAGTCCTCTT); for wild-type HLXB9, PCR 1: HLXB9-624F (5Ј-CTTCCAGCTGGA CCAGTGGCTG) and HLXB9-1090R (CGTCCTCGTCCTCGTC CTCC); PCR 2 HLXB9-651F (5Ј-CACCGCGGGCATGATCCT GC) and HLXB9-989R (5Ј-GGCCCCAGCAGCTCCTCGGCT C); for HLXB9/TEL fusion, HLXB9-624F and TEL-R1 (PCR 1), HLXB9-651F and TEL-R10 (PCR2).
Results and discussion
Morphologic findings
At presentation, the blood of both patients showed a moderate, normochromic, normocytic anemia, and moderate to severe thrombocytopenia. Of note was the marked leukocytosis with a predominance of blasts (63% in RTR and 82% in INS; Figure 1a and b). The blasts themselves showed moderate variability in size, ranging from small to medium. The blasts had mostly round nuclei, reticular nuclear chromatin, one to three distinct nucleoli, and a modest amount of basophilic, largely agranular cytoplasm (Figure 1c and d) . Auer rods were not present.
Both patients showed markedly hypercellular marrow specimens (virtually 100% cellularity) that consisted of 76% and 69% blasts in INS and RTR. In both cases, neutrophilic cells at the promyelocytic and later stages comprised 18% of the marrow aspirate differential count. Mitoses were noted in both the aspirate smears and in sections of the trephine biopsies. Megakaryocytes were decreased in number; dysplastic changes were not noted in the maturing neutrophilic precursors, erythroblasts, or megakaryocytes. Staining of the marrow aspirate smears for myeloperoxidase showed positive reactivity in 14% in RTR and 9% in INS. The findings in each case fulfill the morphologic definition of acute myeloid leukemia with maturation, according to the World Health Organization classification. 27 The similarity in morphologic findings between these two cases was notable.
Defining the chromosome abnormalities
G-banded chromosome analysis of RTR showed a clone comprising 100% of the 20 metaphases analyzed, characterized by a reciprocal translocation between 7q36 and 12p13 and by an extra copy of chromosome 19 (Figure 2a) . The ISCN designation is: 47,XY,t(7;12)(q36;p13),+19. As illustrated in Figure 2 , the t(7;12) is subtle, but was detected by high resolution G-banding prior to FISH. For patient INS, G-banded analysis revealed an abnormal clone in 95% of the 20 metaphases analyzed. This clone was more complex, with bands q11.2 to q36 from the long arm of one chromosome 7 inserted into the short arm of one chromosome 12 at band 12p13 and with trisomies for chromosomes 13 and 19. At first glance, and in metaphase cells of lower G-band resolution, the 7/12 rearrangement appeared to be a simple translocation, with breakpoints at 7q11.1 and 12p13. However, examination of metaphases of increased band level resolution showed involvement of 7q36, with an insertion rather than a simple translocation characterizing this rearrangement (Figure 2b) . Thus, the karyotype is designated as 48,XY,ins(12;7)(p13;q36;q11.1),+13,+19. The presence and orientation of the insertion was confirmed by FISH as shown below.
Although other complex rearrangements of 7q36 and 12p13 have been described, 3 the present case represents the first report of a 7q36/12p13 rearrangement generated by an inserLeukemia tion. The insertion creates a 7q36/12p13 fusion on the derivative chromosome 12, but not a reciprocal fusion on the derivative chromosome 7, supporting previous studies that indicated that the critical event in the t(7;12)(q36;p13) occurs on the derivative chromosome 12.
The finding of two different mechanisms generating the 7q36/12p13 rearrangements in patients RTR and INS has significant implications for the molecular organization of the breakpoint regions. Specifically, on the derivative chromosome 12 in the reciprocal translocation, the translocated 7q36 segment is in telomere → centromere orientation as it joins 12p13. In contrast, in INS the 7q36 sequences on the der (12) are inserted such that their telomere to centromere orientation is inverted relative to that found in a wild-type chromosome 7. As a result, the involved chromosome 7 and 12 sequences are in opposite orientations relative to each other on the der(12) chromosomes from the two cases as illustrated in Figure 3 .
These two G-banded analyses also highlight that involvement of band 7q36 can be subtle or even cryptic in the 7q36;12p13 rearrangements. Several of the patients reported by Tosi et al 2 and Slater et al 1 to have t(7;12)(q36;p13), were initially considered, based on G-banding patterns, to have deletions of 7q with breakpoints at 7q22 or 7q32. Involvement of the t(7;12)(q36;p13) was detected only after FISH. This raises the question of whether this same breakpoint in 7q36 might be involved in other myeloid malignancies characterized by deletions of 7q currently designated as having more proximal breakpoints.
Identification of the breakpoint within TEL by FISH
To determine whether these two patients had breaks in TEL intron 1 or 2, FISH was performed with a series of overlapping cosmid clones spanning the approximately 100 kb intron 1 of TEL. In RTR, hybridization with cosmid 50F4 showed an asymmetrically split signal, with the larger portion localized Ideograms showing (a) the orientation of the 7q36 to 7qterminus segment in RTR and (b) the orientation of the 7q11.2 to 7q36 segment in INS. In RTR, it is the most proximal (centromeric) portion of the involved 7q36 segment that joins to 12p13 whereas in INS, it is the most distal (telomeric) portion of the involved 7q36 segmenet that joins 12p13.
to the der(12) and a minor portion to the der(7) (data not shown). Using the smaller 10A probe derived from the 50F4 cosmid, the breakpoint was more finely localized to an approximately 5 kbp region within intron 1 (Figure 4a) .
In INS, FISH with a TEL probe that included exon 1 and the 5Ј most portion of the intron 1 (179A6) resulted in signal at the telomeric end of the short arm of the der(12) (data not shown). In contrast, hybridization with a TEL probe containing the 3Ј end of intron 1 (50F4) resulted in a signal close to the der(12) centromere (data not shown), confirming the insertion described above. FISH with a TEL probe from the central portion of intron 1 (67C6) revealed an unevenly split signal, with the majority of the signal localizing to the telomeric end and the smaller portion localizing to the centromeric region of the der(12) short arm (Figure 4b) . Thus, the break in TEL in patient INS occurred within the region of intron 1 spanned by the 3Ј-end of cosmid 67C6.
Identification of the breakpoint at 7q36
To position the chromosome 7 breakpoint in RTR we conducted FISH with a series of cosmids mapped to 7q36. In order from centromere to telomere these included: CDK5 (cyclindependent kinase 5), En-2 (human engrailed homologue),
Figure 4
Localization of TEL and 7q36 breakpoints: (a) FISH with probe 10A from TEL cosmid 50F4 shows a split signal on the der(7) and der (12) (12), demonstrating that the breakpoint in 7q36 is distal to this probe. FRS-236 labeled in green, 7 centromeric region labeled in red.
RHEB2 gene (ras homologue expressed in brain; pM118). All of these hybridized to the der(7), indicating that the breakpoint in RTR was distal (telomeric) to these loci (data not shown). We further conducted FISH with cosmid probe FRS-236 that contains the entire HLXB9 (homeobox-HB9) gene. The probe hybridized in its entirety to the der (12) (Figure 4c) , indicating that the break in RTR was proximal (centromeric) to this clone and therefore lies between RHEB2 and HLXB9. This location is consistent with the three cases of t(7;12)(q36;p13) reported by Tosi et al in which the breakpoint was localized within a 130 kbp PAC (HFDJ1121A15). In each case reported by Tosi et al, 2 the breakpoint was proximal to cosmid clones that contained the HLXB9 gene derived from the telomeric end of this PAC. However, two other published cases 2 had breaks either distal or proximal to this PAC. Together, these data indicate that the breaks in chromosome 7 span a region of at least 130 kbp.
In the INS case, cosmid FRS-236 hybridized to sequences at the proximal end of the inserted chromosome 7 sequences on the der(12) chromosome, adjacent to TEL intron 1. Thus, in this patient, the 7q36 breakpoint is distal (telomeric) to HLXB9. This is illustrated in Figure 4d , showing FRS-236 (green) located adjacent to the 12p13 sequences towards the centromere of the der(12) while the chromosome 7 centromeric probe (red) hybridized near the telomere of the der(12).
This result is significant as it confirms that at this level of analysis, the orientation of 7q36 and 12p13 sequences is opposite in patient RTR and INS ( Figure 5 ). As discussed below, the opposite orientation argues against the generation of a common 7q36/TEL fusion gene by RTR and INS.
Molecular definition of the 7;12 breakpoint in patient RTR
As described above, the breakpoint in TEL in patient RTR was localized to an approximately 5 kbp region within TEL intron 1. This relatively small target size, together with the fact that the entire TEL gene and flanking DNA have been sequenced, made it feasible to attempt to clone the breakpoint by inverse PCR (iPCR). To this end, restriction enzyme maps were generated of this region, and DNA from control (293) and patient RTR were digested individually with enzymes that generated fragments of approximately 1 to 3 kbp. The DNA was then self-ligated and used in PCRs with primers complementary to sequences within the target region of TEL as described in Materials and methods and depicted in Figure 6a . With the majority of enzyme/primer combinations, PCR products obtained corresponded to those expected for the wild-type TEL gene (data not shown). However, reactions conducted with ApaLI-digested DNA from RTR showed a faint band corresponding to the predicted 3.6 kbp wild-type PCR product and a second more prominent PCR product of approximately 2.1 kbp (Figure 6b ). This smaller band was purified and sequenced; data obtained ( Figure 6c ) were used for BLAST Leukemia searches (NCBI) that revealed the presence of sequences from TEL intron 1 (from NT 35 049 to 35 105 according to the numbering of cosmid 67C6; GenBank Accession No. U81831) fused to sequences derived from human chromosome number 7, band q36.3 (at NT 52632 according to the numbering of PAC RP5-1121A15; GenBank Accession No. AC006357). To verify that the t(7;12) breakpoint identified by iPCR was authentic, additional PCRs were conducted using patient RTR genomic DNA to directly amplify across the predicted breakpoints on both the der(7) and der(12) chromosomes as described in Materials and methods. As shown in Figure 6c , each of these primer pairs amplified sequences predicted for the der (7) and der(12) chromosomes. Thus, these data clearly define the precise sites of exchange between chromosomes 7 and 12 in this patient and demonstrate that the breakpoint on 7q36.3 is 30 kbp centromeric to the HLXB9 gene.
Search for TEL fusion transcripts
Although the differences between the molecular organization of the 7q36/12p13 breakpoint regions in patients RTR and INS argue against the generation of the same TEL-7q36 fusion transcript, the production of chimeric transcripts is to date, the most common outcome of leukemia-associated translocations. Therefore, considerable time and effort was devoted to conducting 5Ј and 3Ј RACE experiments to find such fusion transcripts in the two patients analyzed here. In all cases, only wild-type TEL transcripts were found, with no evidence for transcripts containing novel sequences fused to either the 5Ј or 3Ј end of TEL-containing transcripts (data not shown).
During the course of these studies, a manuscript was published reporting that in two cases of t(7;12)(q36;p13), transcripts were detected that contained HLXB9 exon 1 fused in frame to exon 3 of TEL as well as transcripts that contained HLXB9 exon 1 fused out of frame to exon 2 of TEL. 5 In agreement with our results, these TEL-containing fusion transcripts were not detectable by 5Ј RACE, but were found only when gene-specific primers were used in PCR reactions. It was suggested that the inability to detect these fusion transcripts by 5Ј RACE was due to the fact that exon 1 of HLXB9 is GC-rich and therefore a poor substrate for reverse transcriptase. The detection of HLXB9-TEL fusion transcripts by Beverloo et al 5 was unusual, as FISH data indicated that HLXB9 was not disrupted by the rearrangement. Generation of HLXB9-TEL fusion transcripts would therefore require that transcription initiate in the HLXB9 gene, proceed through the normal RNA processing sites and through the intervening chromosome 7 sequences into the translocated TEL gene. In patient RTR, this would constitute an extra 30 kbp of 7q sequences. Generation of the reported fusion transcript would further require splicing from HLXB9 5Ј splice donor sites to the TEL 3Ј acceptor site instead of to the normal HLXB9 splice acceptor site. This series of events bears some similarity to events that occur at the MDS/EVI1 locus, [28] [29] [30] although in that case, intergenic splicing is seen in normal cells and in the absence of chromosomal rearrangements. In the case of patient INS, it also seemed unlikely that an HLXB9-TEL fusion transcript could be generated, since FISH data indicated that the HLXB9 and TEL sequences were in opposite orientations ( Figure 5 ). However, since it is possible that the rearrangement in this case is more complex than revealed by FISH, experiments were conducted to specifically search for HLX9-TEL fusion transcripts in each of our patient samples. This was approached by generating random primed cDNA from patients RTR and INS and using this cDNA in PCRs with several different pairs of HLXB9 and TEL gene specific primers for HLXB9 and TEL, analogous to the procedure of Beverloo et al. 5 In contrast to their results, however, all reactions with a combination of HLXB9 and TEL were uniformly negative; an example of one such experiment conducted with RNA from patient RTR is shown in Figure 7 . As shown, RT-PCRs using either two TEL or two HLXB9 gene specific primers resulted in the amplification of the expected wild-type products which are of approximately the same size. However, PCRs using the 5Ј HLXB9 primer in conjunction with a TEL specific 3Ј primer failed to reveal evidence for fusion transcript in RTR or INS (data not shown). These data suggest either that we do not detect HLXB9-TEL fusion transcripts due to a technical problem, or to the possibility that HLXB9-TEL fusion transcripts are not consistently present in patients with the t(7;12)(q36;p13). If the latter were correct, then the importance of these transcripts in the genesis of disease would be in question.
Data presented in this report describe two cases of 7q36/12p13 fusions generated by different kinds of chromosomal rearrangements that result in significantly different molecular organization of the involved 12p13 and 7q36 sequences. This finding, together with the absence of detectable TEL fusion transcripts in patients 1 and 2 analyzed here, suggest that the generation of TEL fusion transcripts might not be a requisite consequence of the 7;12 rearrangement. The 7;12 then joins several other examples in which a role for TEL fusion transcripts has been called into question, either because they are not consistently seen in all patients analyzed or because fusion transcripts detected are unlikely to give rise to novel proteins with clearly identifiable function(s). Despite the differences at the molecular level, the clinical and morphologic correlates of the associated leukemia are remarkably similar between these two patients, arguing for a common etiology. A possibility consistent with our mapping data, and with the absence of detectable TEL-containing fusion mRNAs is that the important consequence of the 7q36;12p13 rearrangement is the disruption of TEL in combination with disruption of a critical locus within 7q36. Generally malignancies involving gene disruptions or deletions are associated with loss of tumor suppressor genes that typically act in a recessive fashion. However, there are an increasing number of examples in which pathologic consequences can be attributed to the heterozygous state. [31] [32] [33] [34] Alternatively the chromosomal rearrangement may result in activation of a gene located in cis to breakpoint. Experiments are underway to further investigate these possibilities.
Figure 7
Absence of detectable HLXB9-TEL fusion transcripts in patient RTR. RNA isolated from patient RTR and from control cells were used in RT-PCR reactions. As shown, both samples give rise to PCR products generated from wild-type TEL and HLXB9 transcripts, but lack detectable HLXB9-TEL fusion transcripts.
